Dopamine D1 receptor mRNA and receptor levels in the striatum of MPTP monkeys chronically treated with SKF-82958
Identifieur interne : 003E15 ( Main/Merge ); précédent : 003E14; suivant : 003E16Dopamine D1 receptor mRNA and receptor levels in the striatum of MPTP monkeys chronically treated with SKF-82958
Auteurs : R. Grondin [Canada] ; M. Goulet [Canada] ; M. Morissette [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada]Source :
- European journal of pharmacology [ 0014-2999 ] ; 1999.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Singe.
English descriptors
- KwdEn :
Abstract
The density of dopamine D1 receptor antagonist sites was measured by autoradiography and dopamine D1 receptor mRNA levels were measured by in situ hybridization in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed monkeys chronically treated with the dopamine D1 receptor agonist 6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1 H-3-benzazepine hydrobromide (SKF-82958) administered in intermittent or continuous mode for a month. Normal and MPTP-exposed but otherwise untreated animals were used for comparison. Intermittent treatment with SKF-82958 relieved parkinsonian features and induced dyskinesias whereas given continuously this drug induced behavioral tolerance without dyskinesias. On the one hand, MPTP treatment tended to increase dopamine D1receptor density in the putamen whereas treatment of MPTP monkeys with SKF-82958, intermittent or continuous, produced a significant increase compared to control animals. On the other hand, dopamine D1 receptor mRNA levels in the putamen appeared to decrease after MPTP lesion and agonist treatment as compared to dopamine D1receptor density. In contrast, an apparent decrease in dopamine D1 receptor density and mRNA levels was observed in the nucleus accumbens of untreated MPTP monkeys whereas treatment of MPTP monkeys with SKF-82958, intermittent or continuous, produced a significant decrease compared to control animals. Thus, neither dyskinesias nor tolerance can be exclusively related to an increase or decrease in striatal dopamine D, receptors, respectively.
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000D50
- to stream PascalFrancis, to step Curation: 001173
- to stream PascalFrancis, to step Checkpoint: 000C62
Links to Exploration step
Pascal:99-0436170Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Dopamine D<sub>1</sub>
receptor mRNA and receptor levels in the striatum of MPTP monkeys chronically treated with SKF-82958</title>
<author><name sortKey="Grondin, R" sort="Grondin, R" uniqKey="Grondin R" first="R." last="Grondin">R. Grondin</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Faculty of Medicine, Laval University</s1>
<s2>Quebec City, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, G1K 7P4</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Molecular Endocrinology Research Unit, Laval University Research Center, 2705 Laurier Blvd</s1>
<s2>Quebec City, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, G1V 4G2</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Neuroscience Research Unit, Laval University Research Center, 2705 Laurier Blvd</s1>
<s2>Quebec City, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, G1V 4G2</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Goulet, M" sort="Goulet, M" uniqKey="Goulet M" first="M." last="Goulet">M. Goulet</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Molecular Endocrinology Research Unit, Laval University Research Center, 2705 Laurier Blvd</s1>
<s2>Quebec City, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, G1V 4G2</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Quebec City, GIK 7P4</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, GIK 7P4</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Morissette, M" sort="Morissette, M" uniqKey="Morissette M" first="M." last="Morissette">M. Morissette</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Molecular Endocrinology Research Unit, Laval University Research Center, 2705 Laurier Blvd</s1>
<s2>Quebec City, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, G1V 4G2</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bedard, P J" sort="Bedard, P J" uniqKey="Bedard P" first="P. J." last="Bedard">P. J. Bedard</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Faculty of Medicine, Laval University</s1>
<s2>Quebec City, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, G1K 7P4</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Neuroscience Research Unit, Laval University Research Center, 2705 Laurier Blvd</s1>
<s2>Quebec City, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, G1V 4G2</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T." last="Di Paolo">T. Di Paolo</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Molecular Endocrinology Research Unit, Laval University Research Center, 2705 Laurier Blvd</s1>
<s2>Quebec City, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, G1V 4G2</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Quebec City, GIK 7P4</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, GIK 7P4</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">99-0436170</idno>
<date when="1999">1999</date>
<idno type="stanalyst">PASCAL 99-0436170 INIST</idno>
<idno type="RBID">Pascal:99-0436170</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000D50</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001173</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000C62</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000C62</idno>
<idno type="wicri:Area/Main/Merge">003E15</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Dopamine D<sub>1</sub>
receptor mRNA and receptor levels in the striatum of MPTP monkeys chronically treated with SKF-82958</title>
<author><name sortKey="Grondin, R" sort="Grondin, R" uniqKey="Grondin R" first="R." last="Grondin">R. Grondin</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Faculty of Medicine, Laval University</s1>
<s2>Quebec City, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, G1K 7P4</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Molecular Endocrinology Research Unit, Laval University Research Center, 2705 Laurier Blvd</s1>
<s2>Quebec City, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, G1V 4G2</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Neuroscience Research Unit, Laval University Research Center, 2705 Laurier Blvd</s1>
<s2>Quebec City, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, G1V 4G2</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Goulet, M" sort="Goulet, M" uniqKey="Goulet M" first="M." last="Goulet">M. Goulet</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Molecular Endocrinology Research Unit, Laval University Research Center, 2705 Laurier Blvd</s1>
<s2>Quebec City, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, G1V 4G2</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Quebec City, GIK 7P4</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, GIK 7P4</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Morissette, M" sort="Morissette, M" uniqKey="Morissette M" first="M." last="Morissette">M. Morissette</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Molecular Endocrinology Research Unit, Laval University Research Center, 2705 Laurier Blvd</s1>
<s2>Quebec City, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, G1V 4G2</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bedard, P J" sort="Bedard, P J" uniqKey="Bedard P" first="P. J." last="Bedard">P. J. Bedard</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Faculty of Medicine, Laval University</s1>
<s2>Quebec City, G1K 7P4</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, G1K 7P4</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Neuroscience Research Unit, Laval University Research Center, 2705 Laurier Blvd</s1>
<s2>Quebec City, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, G1V 4G2</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T." last="Di Paolo">T. Di Paolo</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Molecular Endocrinology Research Unit, Laval University Research Center, 2705 Laurier Blvd</s1>
<s2>Quebec City, G1V 4G2</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, G1V 4G2</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Quebec City, GIK 7P4</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec City, GIK 7P4</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">European journal of pharmacology</title>
<title level="j" type="abbreviated">Eur. j. pharmacol.</title>
<idno type="ISSN">0014-2999</idno>
<imprint><date when="1999">1999</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">European journal of pharmacology</title>
<title level="j" type="abbreviated">Eur. j. pharmacol.</title>
<idno type="ISSN">0014-2999</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term>
<term>Animal</term>
<term>Antiparkinson agent</term>
<term>Brain (vertebrata)</term>
<term>Catecholamine</term>
<term>Central nervous system</term>
<term>Corpus striatum</term>
<term>D1 Dopamine receptor</term>
<term>Dopamine</term>
<term>Dyskinesia</term>
<term>Long term</term>
<term>Monkey</term>
<term>Osmotic pump</term>
<term>Parkinson disease</term>
<term>Putamen</term>
<term>Second messenger</term>
<term>Slow release form</term>
<term>Subcutaneous administration</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antiparkinsonien</term>
<term>Récepteur dopaminergique D1</term>
<term>Agoniste</term>
<term>Parkinson maladie</term>
<term>Dyskinésie</term>
<term>Corps strié</term>
<term>Système nerveux central</term>
<term>Encéphale</term>
<term>Putamen</term>
<term>Animal</term>
<term>Singe</term>
<term>Long terme</term>
<term>Voie souscutanée</term>
<term>Pompe osmotique</term>
<term>Forme libération lente</term>
<term>Dopamine</term>
<term>Catécholamine</term>
<term>Messager secondaire</term>
<term>SKF 82958</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Singe</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The density of dopamine D<sub>1</sub>
receptor antagonist sites was measured by autoradiography and dopamine D<sub>1</sub>
receptor mRNA levels were measured by in situ hybridization in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed monkeys chronically treated with the dopamine D<sub>1</sub>
receptor agonist 6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1 H-3-benzazepine hydrobromide (SKF-82958) administered in intermittent or continuous mode for a month. Normal and MPTP-exposed but otherwise untreated animals were used for comparison. Intermittent treatment with SKF-82958 relieved parkinsonian features and induced dyskinesias whereas given continuously this drug induced behavioral tolerance without dyskinesias. On the one hand, MPTP treatment tended to increase dopamine D<sub>1</sub>
receptor density in the putamen whereas treatment of MPTP monkeys with SKF-82958, intermittent or continuous, produced a significant increase compared to control animals. On the other hand, dopamine D<sub>1</sub>
receptor mRNA levels in the putamen appeared to decrease after MPTP lesion and agonist treatment as compared to dopamine D<sub>1</sub>
receptor density. In contrast, an apparent decrease in dopamine D<sub>1</sub>
receptor density and mRNA levels was observed in the nucleus accumbens of untreated MPTP monkeys whereas treatment of MPTP monkeys with SKF-82958, intermittent or continuous, produced a significant decrease compared to control animals. Thus, neither dyskinesias nor tolerance can be exclusively related to an increase or decrease in striatal dopamine D, receptors, respectively.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
</country>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Grondin, R" sort="Grondin, R" uniqKey="Grondin R" first="R." last="Grondin">R. Grondin</name>
</noRegion>
<name sortKey="Bedard, P J" sort="Bedard, P J" uniqKey="Bedard P" first="P. J." last="Bedard">P. J. Bedard</name>
<name sortKey="Bedard, P J" sort="Bedard, P J" uniqKey="Bedard P" first="P. J." last="Bedard">P. J. Bedard</name>
<name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T." last="Di Paolo">T. Di Paolo</name>
<name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T." last="Di Paolo">T. Di Paolo</name>
<name sortKey="Goulet, M" sort="Goulet, M" uniqKey="Goulet M" first="M." last="Goulet">M. Goulet</name>
<name sortKey="Goulet, M" sort="Goulet, M" uniqKey="Goulet M" first="M." last="Goulet">M. Goulet</name>
<name sortKey="Grondin, R" sort="Grondin, R" uniqKey="Grondin R" first="R." last="Grondin">R. Grondin</name>
<name sortKey="Grondin, R" sort="Grondin, R" uniqKey="Grondin R" first="R." last="Grondin">R. Grondin</name>
<name sortKey="Morissette, M" sort="Morissette, M" uniqKey="Morissette M" first="M." last="Morissette">M. Morissette</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003E15 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 003E15 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Canada |area= ParkinsonCanadaV1 |flux= Main |étape= Merge |type= RBID |clé= Pascal:99-0436170 |texte= Dopamine D1 receptor mRNA and receptor levels in the striatum of MPTP monkeys chronically treated with SKF-82958 }}
![]() | This area was generated with Dilib version V0.6.29. | ![]() |